AI Article Synopsis
- Significant advancements have been made in understanding and treating myelodysplastic syndromes (MDSs), including updates to the World Health Organization classification and new standardized response criteria.
- The International Prognostic Scoring System now offers a consistent framework for managing MDS patients on an individual basis.
- New treatment agents and increased use of stem cell transplants in lower-intensity settings suggest that we may be entering a hopeful era for MDS treatment.
Article Abstract
Over the last several years, there has been substantial progress in the definition, diagnosis, and management of myelodysplastic syndromes (MDSs). This progress includes the new World Health Organization classification and the revised standardized response criteria to be applicable to most new compounds, which, taken together with the International Prognostic Scoring System, provide a uniform basis for the management of individual patients. The recent introduction of certain new agents, as well as an apparent increase in the use of stem cell transplantation with a variety of so-called reduced-intensity settings, has indeed raised the hope that we are entering a new era of MDS treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1532/IJH97.07026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!